Immunic, Inc. (IMUX): Total Liabilities
$30.73M
As of 2025-12-31
$31.59M
As of 2026-06-30
+29.7%
3-year compound annual growth
+27.6%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $30.73M | +36.9% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $22.44M | -11.5% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $25.37M | +80.3% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $14.07M | +17.4% | 2024-02-22, Balance as of period end |
| 2021-12-31 | $11.98M | +32.1% | 2023-02-23, Balance as of period end |
| 2020-12-31 | $9.08M | +19.5% | 2022-02-24, Balance as of period end |
| 2019-12-31 | $7.59M | +295.4% | 2021-02-26, Balance as of period end |
| 2018-12-31 | $1.92M | n/a | 2020-03-16, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Immunic, Inc. (IMUX) | 2025-12-31 | $30.73M | +36.9% |
| Rein Therapeutics, Inc. (RNTX) | 2025-12-31 | $7.24M | -7.2% |
| Kiora Pharmaceuticals Inc (KPRX) | 2025-12-31 | $8.13M | -24.2% |
| HCW Biologics Inc. (HCWB) | 2025-12-31 | $21.76M | -41.2% |
| Integrated Biopharma Inc (INBP) | 2025-06-30 | $4.58M | -34.2% |
| Onconetix, Inc. (ONCO) | 2025-12-31 | $9.16M | -50.7% |
| Faeth Therapeutics, Inc. (FTH) | 2025-12-31 | $4.31M | -38.2% |
| CervoMed Inc. (CRVO) | 2025-12-31 | $4.66M | +20.0% |
| Gain Therapeutics, Inc. (GANX) | 2025-12-31 | $4.25M | -11.1% |
Compare IMUX, RNTX, KPRX, HCWB side by side · Screen every company in Pharmaceutical Preparations ↗